do you think some pretty knowledgeable folks that have brought drugs to market would go through the trouble to open up offices in boston and shanghai and raise close to $100 mil in funding where bavi is the lead drug? and Avid sp reflects prob zero value for the ip right now...
the annual report talks about needing about $5 mil for capital improvements fy 20.... a couple milestone payments from oncologie just might be the source... i also think the cfo will be smart about capital raise and at a decent price if needed....
very good day... prob overbought w rsi but a base to move up from...
News 
Market Data 
Discover 
AI
